| Members |
acceptabilityId |
| [X]X-ray contrast media causing adverse effects in therapeutic use (disorder) |
Preferred (foundation metadata concept) |
| [X]Yaws, unspecified |
Preferred (foundation metadata concept) |
| [X]Yaws, unspecified (disorder) |
Preferred (foundation metadata concept) |
| [X]Yellow fever, unspecified |
Preferred (foundation metadata concept) |
| [X]Yellow fever, unspecified (disorder) |
Preferred (foundation metadata concept) |
| [X]Zoonotic bacterial disease, unspecified |
Preferred (foundation metadata concept) |
| [X]Zoonotic bacterial disease, unspecified (disorder) |
Preferred (foundation metadata concept) |
| [X]Zoster with other complications |
Preferred (foundation metadata concept) |
| [X]Zoster with other complications (disorder) |
Preferred (foundation metadata concept) |
| [X]Zoster without complications |
Preferred (foundation metadata concept) |
| [X]Zoster without complications (disorder) |
Preferred (foundation metadata concept) |
| [X]Zygomycosis, unspecified |
Preferred (foundation metadata concept) |
| [X]Zygomycosis, unspecified (disorder) |
Preferred (foundation metadata concept) |
| [X]other malignant neoplasm of skin of other and unspecified parts of face |
Preferred (foundation metadata concept) |
| [X]other malignant neoplasm of skin of other and unspecified parts of face (disorder) |
Preferred (foundation metadata concept) |
| [X]solvents: [mental & behavioural disorders dependence syndrome due to use of] or [drug addiction] |
Preferred (foundation metadata concept) |
| [X]solvents: [mental & behavioural disorders dependence syndrome due to use of] or [drug addiction] (disorder) |
Preferred (foundation metadata concept) |
| [acetyl-CoA carboxylase] kinase |
Acceptable (foundation metadata concept) |
| ^1^H |
Acceptable (foundation metadata concept) |
| ^2^H |
Acceptable (foundation metadata concept) |
| ^3^H |
Acceptable (foundation metadata concept) |
| ^A^gamma delta beta^0^ thalassaemia |
Preferred (foundation metadata concept) |
| ^A^gamma delta beta^0^ thalassemia (disorder) |
Preferred (foundation metadata concept) |
| a |
Preferred (foundation metadata concept) |
| a |
Preferred (foundation metadata concept) |
| a |
Preferred (foundation metadata concept) |
| a (tumor staging) |
Preferred (foundation metadata concept) |
| a - At autopsy |
Preferred (foundation metadata concept) |
| a - At autopsy (tumor staging) |
Preferred (foundation metadata concept) |
| a and b waves reduced |
Preferred (foundation metadata concept) |
| a and b waves reduced (finding) |
Preferred (foundation metadata concept) |
| a wave |
Preferred (foundation metadata concept) |
| a wave (qualifier value) |
Preferred (foundation metadata concept) |
| a- Naphthylamine |
Acceptable (foundation metadata concept) |
| a-Methyfentanyl |
Acceptable (foundation metadata concept) |
| a.m. peak specimen |
Preferred (foundation metadata concept) |
| a.m. peak specimen |
Preferred (foundation metadata concept) |
| a.m. peak specimen (qualifier value) |
Preferred (foundation metadata concept) |
| a.m. peak specimen (specimen) |
Preferred (foundation metadata concept) |
| a.m. serum specimen |
Preferred (foundation metadata concept) |
| a.m. serum specimen (specimen) |
Preferred (foundation metadata concept) |
| a.m. specimen |
Preferred (foundation metadata concept) |
| a.m. specimen (specimen) |
Preferred (foundation metadata concept) |
| aEEG - amplitude integrated electroencephalography |
Acceptable (foundation metadata concept) |
| aHUS (atypical haemolytic uraemic syndrome) with anti-factor H antibodies |
Acceptable (foundation metadata concept) |
| aHUS (atypical haemolytic uraemic syndrome) with complement gene abnormality |
Acceptable (foundation metadata concept) |
| aHUS - atypical haemolytic uraemic syndrome |
Acceptable (foundation metadata concept) |
| aMCI - amnestic mild cognitive impairment |
Acceptable (foundation metadata concept) |
| aPL - Anti-phospholipid antibody |
Acceptable (foundation metadata concept) |
| aVF |
Preferred (foundation metadata concept) |
| aVF (body structure) |
Preferred (foundation metadata concept) |
| aVL |
Preferred (foundation metadata concept) |
| aVL (body structure) |
Preferred (foundation metadata concept) |
| aVR |
Preferred (foundation metadata concept) |
| aVR (body structure) |
Preferred (foundation metadata concept) |
| aaMAC - age adjusted minimum alveolar concentration |
Acceptable (foundation metadata concept) |
| aaetMAC -age adjusted end tidal minimum alveolar concentration |
Acceptable (foundation metadata concept) |
| ac - ante cibum |
Acceptable (foundation metadata concept) |
| acre |
Preferred (foundation metadata concept) |
| acre (qualifier value) |
Preferred (foundation metadata concept) |
| acute canine polyradiculoneuropathy |
Acceptable (foundation metadata concept) |
| acute myocardial infarction of posterolateral wall (disorder) |
Preferred (foundation metadata concept) |
| adPEO - autosomal dominant progressive external ophthalmoplegia |
Acceptable (foundation metadata concept) |
| akat |
Preferred (foundation metadata concept) |
| alcohol units/day |
Preferred (foundation metadata concept) |
| alcohol units/day (qualifier value) |
Preferred (foundation metadata concept) |
| alcohol units/week |
Preferred (foundation metadata concept) |
| alcohol units/week (qualifier value) |
Preferred (foundation metadata concept) |
| all-trans-Heptaprenyl-diphosphate synthase |
Acceptable (foundation metadata concept) |
| all-trans-Hexaprenyl-diphosphate synthase |
Acceptable (foundation metadata concept) |
| all-trans-Nonaprenyl-diphosphate synthase |
Acceptable (foundation metadata concept) |
| alpha Chloralose |
Preferred (foundation metadata concept) |
| alpha Chloralose (substance) |
Preferred (foundation metadata concept) |
| alpha thalassaemia |
Acceptable (foundation metadata concept) |
| alpha-1,4-Glucosidase deficiency |
Acceptable (foundation metadata concept) |
| alpha-1-Proteinase inhibitor deficiency |
Acceptable (foundation metadata concept) |
| alpha-Amino acid nitrogen measurement |
Preferred (foundation metadata concept) |
| alpha-Amino acid nitrogen measurement (procedure) |
Preferred (foundation metadata concept) |
| alpha-Amino-n-butyrate measurement |
Preferred (foundation metadata concept) |
| alpha-Amino-n-butyrate measurement (procedure) |
Preferred (foundation metadata concept) |
| alpha-Aminoacylpeptide hydrolase |
Preferred (foundation metadata concept) |
| alpha-Aminoacylpeptide hydrolase (biological function) (substance) |
Preferred (foundation metadata concept) |
| alpha-Aminoadipate measurement |
Preferred (foundation metadata concept) |
| alpha-Aminoadipate measurement (procedure) |
Preferred (foundation metadata concept) |
| alpha-Aminoisobutyrate measurement |
Preferred (foundation metadata concept) |
| alpha-Aminoisobutyrate measurement (procedure) |
Preferred (foundation metadata concept) |
| alpha-Amylase (substance) |
Preferred (foundation metadata concept) |
| alpha-Amylase agent |
Acceptable (foundation metadata concept) |
| alpha-Amylase agent (substance) |
Preferred (foundation metadata concept) |
| alpha-Amylase preparation |
Preferred (foundation metadata concept) |
| alpha-Amylase renal clearance |
Preferred (foundation metadata concept) |
| alpha-Amylase renal clearance, function |
Acceptable (foundation metadata concept) |
| alpha-Amylase renal clearance, function (observable entity) |
Preferred (foundation metadata concept) |
| alpha-Chlordane measurement |
Preferred (foundation metadata concept) |
| alpha-Chlordane measurement (procedure) |
Preferred (foundation metadata concept) |
| alpha-Chymotrypsin preparation |
Acceptable (foundation metadata concept) |
| alpha-Galactosidase-A deficiency |
Acceptable (foundation metadata concept) |
| alpha-Glucosidase (substance) |
Preferred (foundation metadata concept) |
| alpha-Glucosidase deficiency |
Acceptable (foundation metadata concept) |
| alpha-Glucosidase measurement |
Preferred (foundation metadata concept) |
| alpha-Glucosidase measurement (procedure) |
Preferred (foundation metadata concept) |
FHIR